Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$1.07 -5.3%	$1.17	$0.66 ▼ $4.20	$130.32M	2.24	1.53 million shs	1.68 million shs
HYPD Hyperion DeFi	$6.69 -5.0%	$8.98	$0.85 ▼ $75.18	$39.44M	2.42	767,143 shs	382,832 shs
MCRB Seres Therapeutics	$16.86 +5.6%	$11.74	$6.53 ▼ $26.40	$139.81M	2.9	126,564 shs	208,903 shs
NKTX Nkarta	$2.20 -0.5%	$1.92	$1.31 ▼ $6.63	$156.96M	0.72	594,389 shs	827,367 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-5.31%	+9.17%	-5.31%	0.00%	-67.28%
HYPD Hyperion DeFi	-4.97%	+21.64%	-48.10%	+492.04%	-89.05%
MCRB Seres Therapeutics	+5.57%	+10.27%	+14.93%	+126.01%	-6.65%
NKTX Nkarta	-0.45%	+9.45%	+20.88%	+26.44%	-57.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FATE Fate Therapeutics	4.066 of 5 stars	3.1	2.0	4.7	2.3	2.5	0.6
HYPD Hyperion DeFi	0.3596 of 5 stars	1.0	0.0	0.0	2.4	0.8	0.6
MCRB Seres Therapeutics	3.2446 of 5 stars	2.9	1.0	4.6	2.7	0.8	0.0
NKTX Nkarta	2.0657 of 5 stars	3.5	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.13	Hold	$3.58	234.89% Upside
HYPD Hyperion DeFi	2.00	Hold	$2.00	-70.10% Downside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	336.93% Upside
NKTX Nkarta	3.00	Buy	$13.60	518.18% Upside

Current Analyst Ratings Breakdown

Latest HYPD, NKTX, FATE, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
8/13/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$13.63M	9.05	N/A	N/A	$2.27 per share	0.47
HYPD Hyperion DeFi	$60K	624.40	N/A	N/A	($695.52) per share	-0.01
MCRB Seres Therapeutics	$126.32M	1.17	N/A	N/A	$3.76 per share	4.48
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-369.98%	N/A
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
NKTX Nkarta	-$108.79M	-$1.48	N/A	N/A	N/A	N/A	-27.74%	-22.38%	N/A

Latest HYPD, NKTX, FATE, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	8.04	8.81
HYPD Hyperion DeFi	N/A	0.34	0.34
MCRB Seres Therapeutics	N/A	1.57	1.57
NKTX Nkarta	N/A	15.67	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
HYPD Hyperion DeFi	25.84%
MCRB Seres Therapeutics	59.34%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	5.51%
HYPD Hyperion DeFi	10.86%
MCRB Seres Therapeutics	4.70%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	115.33 million	108.29 million	Optionable
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
NKTX Nkarta	140	71.03 million	65.00 million	Optionable

HYPD, NKTX, FATE, and MCRB Headlines

Recent News About These Companies

Needham & Company LLC Reiterates "Buy" Rating for Nkarta (NASDAQ:NKTX)

2 hours ago | americanbankingnews.com

Nkarta price target lowered to $12 from $14 at Stifel

3 hours ago | msn.com

Nkarta (NASDAQ:NKTX) Announces Earnings Results, Beats Estimates By $0.06 EPS

August 14 at 6:46 PM | marketbeat.com

Nkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 13 at 7:37 AM | finanznachrichten.de

Nkarta, Inc. Reports Q2 2025 Financial Results

August 12 at 12:25 AM | tipranks.com

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 12 at 4:01 PM | globenewswire.com

Nkarta (NKTX) Projected to Post Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Nkarta (NKTX) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Monaco Asset Management SAM Invests $1.50 Million in Nkarta, Inc. (NASDAQ:NKTX)

July 31, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

July 30, 2025 | marketbeat.com

Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series

July 23, 2025 | tmcnet.com

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

July 23, 2025 | globenewswire.com

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

July 22, 2025 | seekingalpha.com

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

June 27, 2025 | uk.finance.yahoo.com

Nkarta, Inc. (NKTX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 7, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.comQ

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD, NKTX, FATE, and MCRB Company Descriptions

Fate Therapeutics NASDAQ:FATE

$1.07 -0.06 (-5.31%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.17 +0.10 (+9.25%)

As of 04:06 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Hyperion DeFi NASDAQ:HYPD

$6.69 -0.35 (-4.97%)

As of 08/14/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Seres Therapeutics NASDAQ:MCRB

$16.86 +0.89 (+5.57%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$16.91 +0.05 (+0.27%)

As of 04:02 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$2.20 -0.01 (-0.45%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.20 0.00 (0.00%)

As of 08/14/2025 07:32 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time